Prof Nicolas Girard speaks to ecancer about the SOHO-01 study.

He reviews safety data from the SOHO-01 trial focusing on diarrhoea associated with sevabertinib, an oral HER2-targeted therapy for advanced non-small cell lung cancer.

While diarrhoea was common, including some higher-grade events, it typically occurred early, was short in duration, and was effectively managed with dose adjustments and supportive care such as loperamide.

Importantly, these side effects did not appear to compromise treatment efficacy.

These findings provide valuable practical insights into managing a key toxicity of HER2-targeted therapy and support the continued use of sevabertinib as an effective treatment option in this patient population.